|Articles|October 24, 2022
How CDMOs Can Support Nanoparticles for Gene Therapy, Immuno-Oncology, and Vaccines
Author(s)Emergent CDMO
Many CDMOs outsource their nanoparticle supply chain, but in house manufacturing of nanoparticles at CDMOs is anticipated to create new market opportunities.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Novel Delivery Approaches of Biopharmaceuticals 2025
2
FAQ: What You Need to Know about the Current Antibody Pipeline
3
Samsung Biologics Bolsters US Manufacturing Network with GSK Facility Buy
4
GSK and CAMP4 Partner to Advance RNA-Targeting Therapeutics
5